Pretomanid

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.

Pretomanid is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Monkeypox

Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 Pandemic

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
- Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
- Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
- Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
- Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.

There's more to see -- the rest of this topic is available only to subscribers.